Chiral Iridium Aqua Complex for Asymmetric Transfer Hydrogenation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing optically active hydroxy compounds through asymmetric transfer hydrogenation using iridium complexes face limitations in efficiency and selectivity, particularly in the development of novel chiral iridium aqua complexes that can effectively catalyze such reactions.

Innovation Solution

A novel chiral iridium aqua complex represented by the formula (5) is developed, which includes an aryl group substituted by haloalkyl groups, reacted with a chiral diamine, and used for asymmetric transfer hydrogenation in the presence of formic acid or its salt, allowing for the production of optically active hydroxy compounds with high stereoselectivity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional iridium complexes are used for asymmetric transfer hydrogenation, then the reaction can proceed, but the efficiency and selectivity are limited

Engineering Contradiction:
Improvereaction efficiencyVSAvoidstereoselectivity
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The patent applies asymmetry by introducing chiral diamine ligands (formula 11) with specific stereochemical configurations (R,R or S,S) to create chiral iridium complexes. This asymmetric ligand environment around the iridium center enables the catalyst to distinguish between enantiotopic faces of the carbonyl substrate, achieving high stereoselectivity in the formation of optically active hydroxy compounds. The chiral diamine ligands provide a well-defined asymmetric pocket that controls the stereochemical outcome of the hydrogenation reaction.

Inventive Principle:
Principle #4Asymmetry

Solution Approach 2:

The patent employs parameter changes by systematically varying the molecular structure of the iridium complex, including the nature of the aryl group (formula 5), the chiral diamine ligand structure (formula 11), and the counterion (formula 6). By adjusting these structural parameters, the catalyst achieves optimized balance between reaction efficiency and stereoselectivity. The specific combination of iridium center, chiral diamine ligands, and aryl group substituents creates a catalyst system with enhanced catalytic activity and high enantioselectivity.

Inventive Principle:
Principle #35Parameter changes

2Manufacturing precision

If novel chiral iridium aqua complexes are developed to improve stereoselectivity, then optical purity increases, but complex synthesis complexity increases

Engineering Contradiction:
Improveoptical purityVSAvoidcomplex synthesis complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the complex synthesis into distinct modular steps: (1) preparation of the chiral diamine ligand (formula 11) with specific stereochemistry, (2) formation of the iridium complex core, and (3) assembly of the complete chiral iridium aqua complex (formula 5). This modular approach allows each component to be optimized independently and simplifies the overall synthesis process by avoiding the need to build complexity in a single step.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent uses chiral diamine ligands (formula 11) as intermediary components that mediate between the iridium center and the substrate. These ligands serve as chiral information carriers that transmit stereochemical control from the catalyst to the reaction outcome. The ligands facilitate the formation of the active catalytic species while maintaining chiral integrity, enabling high optical purity without requiring overly complex direct catalytic systems.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If the complex is designed for high stability in aqueous solutions, then reliability improves, but reaction rate may decrease

Engineering Contradiction:
Improvestability in aqueous solutionsVSAvoidreaction rate
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies local quality by creating a hydrophilic aqueous reaction environment while maintaining the chiral iridium complex's structural integrity. The complex is designed with appropriate solubility characteristics that allow it to function reliably in water or aqueous mixed solvents. The local chemical environment around the iridium center is optimized to maintain stability in water while still enabling efficient substrate binding and transformation. This approach allows the catalyst to operate in environmentally friendly aqueous conditions without sacrificing activity.

Inventive Principle:
Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The novel chiral iridium aqua complex achieves high yields and stereoselectivity in producing optically active hydroxy compounds, demonstrating improved efficiency and stability in aqueous solutions, making it suitable for green chemistry applications.

Implementation Method 1

a production method of an optically active hydroxy compound by asymmetric transfer hydrogenation using the complex

Methodology Applied
Scientific EffectAsymmetric transfer hydrogenation: Catalysis

Implementation Method 2

asymmetric transfer hydrogenation of a carbonyl compound to produce an optically active hydroxy compound

Methodology Applied
Scientific EffectHydrogenation: Hydrogenation

Data Source

PatentEP2123661B1Chiral iridium aqua complex and method for producing optically active hydroxy compound by using the same
Publication Date: 2013.05.22 SUMITOMO CHEM CO LTD
  • EP2123661B1 patent drawing
  • EP2123661B1 patent drawing
  • EP2123661B1 patent drawing

AI summary

The present invention provides a novel chiral iridium aqua complex used for asymmetric transfer hydrogenation. The present invention relates to chiral iridium aqua complex represented by the formula (1): wherein R1 and R2 are the same or different and each is an aryl group optionally having at least one substituent selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkoxy group having 1 to 6 carbon atoms, a nitro group, a carboxyl group and a cyano group, or the like; and R3 and R4 are the same or different and each is an alkyl group or the like.